{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"63.9"},{"groupId":"OG001","value":"75.5"},{"groupId":"OG002","value":"59.4"},{"groupId":"OG003","value":"65.0"},{"groupId":"OG004","value":"61.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"159"},{"groupId":"OG002","value":"96"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"243"}],"units":"Participants"}],"description":"An Adverse Event (AE) is any untoward medical occurrence in a patient or clinical investigation subject administered a pharmaceutical product, which does not necessarily have a causal relationship with this treatment. An AE could therefore be any unfavorable and unintended sign, symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product.","groups":[{"description":"Matching placebo to certolizumab pegol (CZP) injections were administered every 2 weeks from Week 0 onwards. Subjects formed the Safety Set (SS).","id":"OG000","title":"Placebo (SS)"},{"description":"Certolizumab pegol (CZP) 400 mg subcutaneous (sc) on Weeks 0, 2 and 4, followed by 200 mg CZP sc every 2 weeks (Q2W) from Week 6 onwards. Subjects formed the SS.","id":"OG001","title":"CZP 200 mg Q2W (SS)"},{"description":"Subset of subjects from the Placebo group, who discontinued the CZP double-blind treatment and entered the open-label CZP treatment. The subjects were included in the SS for safety analysis.","id":"OG002","title":"Placebo->OL CZP (SS)"},{"description":"Subset of subjects from the CZP 200 mg Q2W group, who discontinued the CZP double-blind treatment and entered the CZP open-label treatment. The subjects were included in the SS for safety analysis.","id":"OG003","title":"CZP->OL CZP (SS)"},{"description":"Subjects who completed Double-Blind Period received CZP 200 mg at Week 52, 54 and 56 to maintain the blinding and who completed the Week 52 Visit on placebo treatment received loading doses of CZP 400 mg at these visits. Subjects who completed the Week 52 Visit on CZP treatment received 1 injection of CZP 200 mg and 1 injection of placebo at these visits to continue their previous CZP treatment regimen and subjects who discontinued from Double-Blind Period and entered OL CZP treatment continued their OL CZP treatment regimen during SFE Period. The subjects were included in the SS for safety analysis. Subjects received CZP 200 mg Q2W for up to 2 years during the SFE Period. An additional signed informed consent for the SFE was a pre-requisite For the additional milestone one (Received OL CZP; Completed Week 52 without starting SFE) reported in Double-Blind Period (Week 0 -52).","id":"OG004","title":"SFE OL CZP 200 mg Q2W (SS)"}],"paramType":"NUMBER","populationDescription":"The SS consisted of all subjects who received at least 1 dose of study treatment.","reportingStatus":"POSTED","timeFrame":"From Baseline up to the End of Safety Follow-up Extension Period (up to Week 156)","title":"Percentage of Subjects With Treatment-Emergent Adverse Events (TEAEs) During the Study","type":"SECONDARY","unitOfMeasure":"percentage of subjects"}